How to Get AndroGel in South Dakota

Who Qualifies for an AndroGel Prescription in South Dakota

AndroGel is FDA-approved exclusively for men with confirmed hypogonadism, defined as a clinical syndrome resulting from insufficient testosterone production 1. Getting a prescription in South Dakota starts with meeting the diagnostic criteria established by the Endocrine Society.

The Two-Sample Diagnostic Standard

The Endocrine Society's 2018 clinical practice guideline requires at least two morning serum total testosterone measurements below 300 ng/dL, drawn between 7:00 and 10:00 AM when levels peak 2. Samples should be collected on separate days. This two-sample rule exists because testosterone levels fluctuate day to day by as much as 15 to 25% in individual men 3. A single low result is not sufficient for diagnosis.

Required Lab Work

Before prescribing testosterone gel, South Dakota providers typically order a panel that includes total testosterone, free testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), a complete blood count with hematocrit, a comprehensive metabolic panel, lipid profile, and prostate-specific antigen (PSA) for men over 40 2. LH and FSH levels help differentiate primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary or hypothalamic origin). The American Urological Association also recommends baseline hematocrit measurement, since testosterone therapy can increase red blood cell production and raise the risk of polycythemia 4.

Symptoms That Support Diagnosis

Lab values alone do not justify treatment. The guideline specifies that low testosterone must be accompanied by symptoms such as decreased libido, erectile dysfunction, fatigue, loss of muscle mass, increased body fat, depressed mood, or reduced bone mineral density 2. Providers document these symptoms before initiating therapy.

Telehealth Prescribing for AndroGel in South Dakota

South Dakota permits telehealth prescribing of testosterone gel, which is significant for residents in rural areas where endocrinologists and urologists are scarce. The state has only 1.3 endocrinologists per 100,000 people, below the national average.

How a Telehealth Visit Works

A licensed telehealth provider conducts a video consultation, reviews lab work (which can be drawn at any Quest, Labcorp, or local hospital lab), evaluates symptoms, and issues a prescription if diagnostic criteria are met. South Dakota law requires that the prescribing clinician hold a valid South Dakota medical license or be practicing under a recognized interstate compact 5. Because AndroGel is a Schedule III controlled substance under the DEA, telehealth prescribers must hold an active DEA registration 1.

Prescriber Types in South Dakota

MDs and DOs can prescribe AndroGel without restriction. Nurse practitioners (NPs) in South Dakota gained full practice authority in 2017, allowing them to prescribe Schedule III substances independently. Physician assistants (PAs) may prescribe under a collaborative agreement with a supervising physician. All three prescriber types must carry Schedule III DEA registration to write testosterone prescriptions 4.

Timeline From Consultation to Delivery

Most patients complete the process in 7 to 14 days. Lab work takes 2 to 4 business days for results. A telehealth consultation can be scheduled within 1 to 3 days after labs return. Once the prescription is issued, pharmacy fulfillment (including shipping from a mail-order or 503A pharmacy) adds another 3 to 5 business days.

Pharmacy Access and 503A Compounding in South Dakota

AndroGel is available at retail pharmacies throughout South Dakota, including CVS, Walgreens, and independent pharmacies in Sioux Falls, Rapid City, and Aberdeen. However, the brand-name price often exceeds $500 per month without insurance.

503A Compounding as a Cost Alternative

South Dakota licenses 503A compounding pharmacies to prepare testosterone gel formulations based on individual prescriptions 6. These pharmacies compound testosterone gel at concentrations matching the prescriber's order, typically at 30 to 70% less than brand-name AndroGel. A 503A pharmacy must compound in response to an individual patient prescription, not in bulk, and must comply with state Board of Pharmacy regulations and USP 795 standards 6.

Shipping and Transfer Rules

503A pharmacies licensed in South Dakota may ship compounded testosterone gel directly to patients within the state. Patients transferring an existing AndroGel prescription from another state can do so by having their out-of-state pharmacy contact a South Dakota pharmacy directly. South Dakota accepts prescription transfers for Schedule III controlled substances between licensed pharmacies, though some pharmacies require verification calls that add 1 to 2 business days.

Insurance Coverage and Prior Authorization in South Dakota

Coverage for AndroGel varies widely by plan type. South Dakota Medicaid does not cover AndroGel for male hypogonadism, which presents a barrier for lower-income patients.

Commercial Insurance

Most commercial plans in South Dakota (Avera Health Plans, Sanford Health Plan, DAKOTACARE) cover testosterone replacement therapy but frequently require prior authorization. The prior authorization process typically requires documentation of two low morning testosterone levels, a clinical note describing symptoms, and confirmation that the patient has no contraindicated conditions such as untreated severe sleep apnea, uncontrolled heart failure, or PSA above 4 ng/mL without urological evaluation 7.

What Prior Authorization Documentation Requires

Insurers in South Dakota generally request the following for AndroGel approval: the two laboratory reports showing total testosterone below 300 ng/dL with dates and times of collection, a signed physician attestation of hypogonadal symptoms, baseline hematocrit and PSA values, and a statement confirming that the patient is not seeking testosterone for age-related decline alone 2. The FDA's 2015 label update explicitly narrowed the indication to men with hypogonadism caused by identifiable conditions (genetic, structural, or pathologic) rather than age-related low testosterone 8.

Managing Denials

If an initial prior authorization is denied, patients can appeal. The Endocrine Society's guideline provides clinical evidence supporting testosterone therapy in symptomatic men with consistently low levels, which serves as useful supporting documentation for appeals 2. Switching to generic testosterone gel 1% (authorized generic of AndroGel) or a 503A compounded formulation may also bypass formulary restrictions.

Clinical Evidence Behind Testosterone Gel Therapy

The evidence base for testosterone gel rests on several large trials that inform prescribing decisions in South Dakota and nationwide.

The Testosterone Trials (TTrials)

The TTrials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with total testosterone below 275 ng/dL, demonstrated that testosterone gel (AndroGel 1%) improved sexual function, physical activity, and mood over 12 months 9. The sexual function trial showed a median increase in the Psychosexual Daily Questionnaire score of 0.58 in the testosterone group versus a decline of 0.02 in placebo (P<0.001) 9.

TRAVERSE Cardiovascular Safety Trial

The TRAVERSE trial (N=5,246), published in 2023 in the New England Journal of Medicine, was the first adequately powered randomized trial to assess cardiovascular safety of testosterone replacement. The incidence of major adverse cardiovascular events was 7.0% in the testosterone group versus 7.3% in the placebo group (hazard ratio 0.96, 95% CI 0.78 to 1.17), establishing non-inferiority for the primary cardiovascular endpoint 10.

Bone Density Findings

A sub-study of the TTrials found that one year of testosterone gel significantly increased volumetric bone mineral density at the spine by 7.5% and estimated bone strength by 10.8% compared to placebo, as measured by quantitative CT 11. These gains were most pronounced in the trabecular compartment. For South Dakota men with both hypogonadism and osteoporosis risk, this benefit adds clinical weight to the treatment decision.

Hematocrit and Safety Monitoring

Polycythemia (hematocrit above 54%) is the most common adverse effect of testosterone therapy, reported in approximately 5 to 6% of treated men in clinical trials 10. The Endocrine Society recommends checking hematocrit at baseline, at 3 to 6 months, and then annually 2. If hematocrit exceeds 54%, the guideline recommends dose reduction, temporary discontinuation, or therapeutic phlebotomy.

How to Use AndroGel Correctly

Proper application technique affects both efficacy and safety, particularly the risk of secondary transfer to household contacts.

Application and Absorption

AndroGel 1.62% is applied once daily to clean, dry skin on the shoulders and upper arms. The gel dries within 5 to 10 minutes. Patients should not shower or swim for at least 2 hours after application to ensure absorption 1. Steady-state serum testosterone levels are typically achieved within 30 days of consistent daily application 12.

Preventing Secondary Transfer

The FDA issued a black-box warning on all testosterone gel products regarding the risk of secondary exposure, particularly to women and children 8. Patients must wash hands thoroughly with soap and water after application, cover the application site with clothing once dry, and wash the site before skin-to-skin contact with others. Reported cases of virilization in children from accidental exposure underscore the importance of these precautions 1.

Ongoing Monitoring After Starting AndroGel

Testosterone therapy is not a set-and-forget treatment. South Dakota providers follow the Endocrine Society's monitoring schedule.

Follow-Up Lab Schedule

The recommended timeline calls for total testosterone, hematocrit, and PSA measurements at 3 months, 6 months, and 12 months after initiation, then annually 2. The target serum testosterone range on therapy is 450 to 600 ng/dL measured mid-morning. Levels above 750 ng/dL suggest dose reduction 4.

When to Reassess or Discontinue

If a patient shows no symptomatic improvement after 3 to 6 months despite testosterone levels in the therapeutic range, the Endocrine Society recommends reassessing the diagnosis and considering discontinuation 2. Testosterone therapy should also be paused if hematocrit exceeds 54% or if PSA rises above 4 ng/mL without a prior urological evaluation 4.

Bone Density Monitoring

For men started on testosterone partly for low bone density, the AUA recommends a follow-up DXA scan at 1 to 2 years to assess treatment response 4. The TTrials bone sub-study found measurable density gains by 12 months, making this a reasonable follow-up interval 11.